ACACIA PHARMA news, videos and press releases - Page 2
For more news please use our advanced search feature.
ACACIA PHARMA - More news...
ACACIA PHARMA - More news...
- Publication of Annual Report 2020
- Results for the year ended 31 December 2020
- Notice of Full Year 2020 Results
- Total Number of Voting Rights and Capital
- Transparency Notification
- Transparency Notification
- Issue of Equity on Exercise of Options/Vesting of Performance Share Awards
- Admission to Trading on Euronext Brussels
- Results of Placing – EUR 27 million Raised to Invest Further in US Launch and Commercialization Activities
- Proposed Capital Raising by way of a Placing of New Ordinary Shares and Update on Early Positive Market Reception to US Launch of BARHEMSYS®
- Change of EU home Member State
- Issue of Equity on Exercise of Options/Vesting of Performance Share Awards
- Issue of Equity on Exercise of Options/Vesting of Performance Share Awards
- Acacia Pharma Launches BYFAVO™ (remimazolam) in the United States for Procedural Sedation in Adults Undergoing Medical Procedures Lasting 30 Minutes or Less
- Acacia Pharma to present at the Upcoming Degroof Petercam Virtual Healthcare Conference
- Issue of Equity on Exercise of Options/Vesting of Performance Share Awards
- Acacia Pharma wins BEL Small Company of the Year for the second consecutive year
- Holding(s) in Company
- Holding(s) in Company
- Holding(s) in Company
- Admission to Trading on Euronext Brussels
- Publication of Supplementary Prospectus
- Correction: Acacia Pharma Announces Amendment of its Investment Agreement with Cosmo Pharmaceuticals for BYFAVO™
- Acacia Pharma Announces Amendment of its Investment Agreement with Cosmo Pharmaceuticals for BYFAVO™
- Director/PDMR Shareholding
- Director/PDMR Shareholding
- Issue of Shares to Employee Benefit Trust
- Acacia Pharma completes drawdown from €25 million loan facility from Cosmo Pharmaceuticals to support US launches of BARHEMSYS® and BYFAVO™
- Acacia Pharma announces BYFAVO™ (remimazolam), its Newly Approved Product for Procedural Sedation, Clears Final Hurdle on Path to Commercial Launch in the US
- BARHEMSYS® (amisulpride injection) Launched in the US for the Treatment and Prevention of PONV